瑞舒伐他汀与阿托伐他汀对冠心病心绞痛患者BNP、NT-proBNP的影响分析

Effect analysis of rosuvastatin and atorvastatin on BNP,NT-proBNP in patients with angina pectoris of coronary atherosclerotic heart diseas

目的 探究瑞舒伐他汀与阿托伐他汀对冠心病心绞痛患者血清B型脑利钠肽(BNP)、N末端B型利钠肽前体(NT-proBNP)的影响。方法 82例冠心病心绞痛患者,随机分为对照组和观察组,每组41例。对照组接受阿托伐他汀治疗,观察组接受瑞舒伐他汀治疗。比较两组患者治疗效果、不良反应发生情况及治疗前后心肌损伤标志物(BNP、NT-proBNP)、血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]水平。结果 观察组治疗总有效率为97.56%,与对照组的87.80%比较差异无统计学意义(P>0.05)。治疗后,观察组患者BNP、NT-proBNP水平分别为(13.27±4.36)、(299.78±51.47)pg/ml,均低于对照组的(16.45±3.98)、(334.46±42.33)pg/ml,差异具有统计学意义(P<0.05)。治疗后,观察组患者TG、TC、LDL-C水平分别为(1.49±0.20)、(3.97±0.29)、(2.58±0.51)mmol/L,均低于对照组的(1.68±0.27)、(4.55±1.10)、(3.04±0.76)mmol/L,差异具有统计学意义(P<0.05);两组患者HDL-C水平比较差异无统计学意义(P>0.05)。观察组不良反应发生率为4.88%,低于对照组的19.51%,差异具有统计学意义(P<0.05)。结论 与阿托伐他汀相比,应用瑞舒伐他汀对冠心病心绞痛患者进行治疗可降低患者心肌损伤,改善其血脂水平,且治疗安全性理想。

Objective To investigate the effect of rosuvastatin and atorvastatin on serum brain natriuretie peptide(BNP),N-terminal pro-B type natriuretic peptide(NT-proBNP) in patients with angina pectoris of coronary atherosclerotic heart disease.Methods A total of 82 patients with angina pectoris of coronary atherosclerotic heart disease were randomly divided into a control group and an observation group,with 41 cases in each group.The control group received atorvastatin treatment,and the observation group received resulvastatin treatment.Both groups were compared in terms of therapeutic effect,occurrence of adverse reactions,levels of myocardial injury marker(BNP,NT-proBNP) and lipid indexes [triglycerides(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)] before and after treatment.Results The total effective rate of treatment in the observation group was 97.56%,and the difference was not statistically significant compared with 87.80% in the control group(P>0.05).After treatment,the BNP and NT-proBNP levels in the observation group were(13.27±4.36) and(299.78±51.47) pg/ml,which were lower than(16.45±3.98) and(334.46±42.33) pg/ml in the control group,and the differences were all statistically significant(P0.05).The incidence of adverse reactions in the observation group was 4.88%,which was lower than 19.51% in the control group,and the difference was statistically significant(P<0.05).Conclusion Compared with atorvastatin,rosuvastatin can reduce myocardial injury and improve blood lipid level in patients with angina pectoris of coronary atherosclerotic heart disease with ideal safety.